Research papers
Selected papers from the last two years
Liang F, Peng L, Wu Z, Giamas G, Stebbing J.
Design and reporting of phase III oncology trials with prospective biomarker validation.
Journal of the National Cancer Institute, 2023;115:174-180
Cereser B, You A, Tabassum N, Belluz LDB, Zagorac S, Ancheta KRZ, Zhong R, Miere C, Jeffries-Jones A, Moderau N, Werner B, J
The mutational landscape of the adult healthy parous and nulliparous human breast.
Nature Communications, 2023;14:1536.
Stebbing J, Takis PG, Sands PJ, Maslin L, Lewis MR, Gleason K, Page K, Guttery D, Fernandez-Garcia D, Primrose L, Shaw JA.
. Comparison of phenomics and cfDNA in a large breast screening population: the Breast Screening and Monitoring Study (BSMS).
Oncogene, 2023;11:825-832.
Agenarelli A, Betran AL, Papakyriacou A, Vella V, Samuels M, Papastaolopous P, Giamas C, Mancini EJ, Stebbing J, Spencer J, Kilabrasi C, Ditsiou A, Giamas G.
The inhibitory properties of a novel, selective LMTK3 inhibitor.
International Journal of Molecular Sciences, 2023;24:865.
Salmerón Ríos S, Cortés Zamora EB, Avendaño Céspedes A, Romero Rizos L, Sánchez-Jurado PM, Sánchez-Nievas G, Mas Romero M, Tabernero Sahuquillo MT, Blas Señalada JJ, Murillo Romero A, García Nogueras I, Estrella Cazalla JD, Andrés-Pretel F, Lauschke VM, Stebbing J, Abizanda P.
Immunogenicity after 6 months of BNT162b2 vacccination in frail or disabled nursing home residents: The COVID-A study.
Journal of the American Geriatric Society, 2022;70:650-658.
Richardson P, Stebbing J.
Baricitinib as the treatment of choice for hospitalised patients with COVID-19.
EClinicalmedicine, 2022;49:101493.
Richardson PJ, Robinson BWS, Smith DP, Stebbing J.
The AI-assisted identification and clinical efficacy of baricitinib in the treatment of COVID-19.
Vaccines, 2022;10:951.
Shapira S, Ben Shmon M, Hay-Levi M, Shenber G, Chosen G, Bannon L, Tepper M, Kazanov D, Seni J, Lev-Ari S, Peer M, Boubas D, Stebbing J, Tsiodras S, Arber N.
A platform for attenuating immune hyperactivity using exosomes displaying CD24 (EXO-CD24) in Coronavirus Disease-2019.
EMBO Molecular Medicine, 2022;14:e15997.
Stebbing J, Nievas GS, Falcone M, Youhanna S, Richardson P, Ottaviani S, Shen JX, Sommerauer C, Tiseo G, Ghiadoni L, Virdis A, Monzani F, Rizos LR, Forfori F, Céspedes AA, De Marco S, Carrozzi L, Lena F, Sánchez-Jurado PM, Lacerenza LG, Cesira N, Bernardo DC, Perrella A, Niccoli L, Méndez LS, Matarrese D, Goletti D, Tan YJ, Monteil V, Dranitsaris G, Cantini F, Farcomeni A, Dutta S, Burley SK, Zhang H, Pistello M, Li W, Romero MM, Pretel FA, Simón-Talero RS, García-Molina R, Kutter C, Felce JH, Nizami ZF, Miklosi AG, Penninger JM, Menichetti F, Mirazimi A, Abizanda P, Lauschke VM.
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
Science Advances, 2021;7:eabe4724.
Sims JT, Krishnan V, Chang C-Y, Engle SM, Casalini G, Rodgers GH, Bivi N, Nickoloff BJ, Konrad RJ, de Bono S, Higgs RE, Benschop RJ, Ottaviani S, Cardosa A, Nirula A, Corbellino M, Stebbing J.
Characterization of the Cytokine Storm Reflects Hyperinflammatory Endothelial Dysfunction in COVID-19.
Journal of Allergy and Clinical Immunology, 2021;147:107-111.
Stebbing J, Lauschke V.
JAK inhibitors: more than glucocorticoids.
New England Journal of Medicine, 2021;385(5):463-465.
Kalil AC, Stebbing J.
Baricitinib: The first immunomodulatory treatment for COVID-19 to demonstrate mortality reduction in a placebo-controlled double-blind study.
The Lancet Respiratory Medicine, 2021;S2213-2600(21)00358-1.
Melikhov O, Kruglova T, Lytkina K, Melkonyan G, Prokhorovich E, Putsman G, Rodoman G, Vertkin A, Zagrebneva A, Stebbing J.
The use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
Annals of Rheumatic Diseases, 2021;80:1245-1246.
Salmerón Ríos S, Mas Romero M, Cortés Zamora EB, Tabernero Sahuquillo MT, Romero Rizos L, Sánchez-Jurado PM, Sánchez-Nievas G, Blas Señalada JJ, García Nogueras I, Estrella Cazalla JD, Andrés-Pretel F, Murillo Romero A, Lauschke VM, Stebbing J, Abizanda P.
Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study.
Journal of the American Geriatric Society, 2021;69:1441-1447.
Pallett SJC, Denny SJ, Patel A, Charani E, Mughal N, Stebbing J, Davies GW, Moore LSP.
Point-of-care SARS-CoV-2 serological assays for enhanced case finding in a UK inpatient population.
Scientific Reports, 2021;11:5860.
Majra D, Benson J, Pitts C, Stebbing J.
SARS-CoV-2 superspreader events.
Journal of Infection, 2021;82:36-40.
Lenz HJ, Richardson P, Stebbing J.
The emergence of baricitinib: a story of tortoises versus hares.
Clinical Infectious Diseases, 2021;72:1251-1254.
Abizanda P, Calbo Mayo MM, Mas Romero M, Cortes Zamora EB, Tabernerno Sahuquillo MTT, Romero Rizos LR, Sanchez-Jurado PM, Sanchez-Nevas G, Andres-Pretel F, Lauschke VM, Stebbing J.
Baricitinib significantly reduces 30-day mortality in older adults with severe COVID-19 pneumonia.
Journal of the American Geriatric Society, 202169:2752-2758;.
Zhang H, Han H, He T, Labbe KE, Hernandez-Diaz A, Chen H, Velcheti V, Stebbing J, Wong KK.
Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis.
Journal of the National Cancer Institute, 2021;113:371-380. *joint last author.
Zhang H, Han H, He T, Labbe KE, Hernandez-Diaz A, Chen H, Velcheti V, Stebbing J, Wong KK.
Letter in Response to Cottu, Bozec, Basse, and Paoletti.
Journal of the National Cancer Institute, 2021;113:344-345.
Page K, Martinson LJ, Hastings RK, Fernandez-Garcia D, Gleason KLT, Gray MC, Rushton AJ, Goddard K, Guttery DS, Stebbing J, Coombes RC, Shaw JA.
Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded mutation assays.
Annals of Oncology, 2021;S0923-7534.
Cilibrasi C, Ditsiou A, Papakyriakou A, Mavridis G, Eravci M, Stebbing J, Gagliano T, Giamas G.
LMTK3 inhibition affects microtubule stability.
Molecular Cancer, 2021;20:53.
Stebbing J, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Pikiel J, Eniu AE, Li RK, Tiangco B, Lee SJ, Kim S.
Long term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
Breast Cancer Research and Treatment, 2021;188:631-640.
Page K, Martinson LJ, Fernandez-Garcia D, Hills A, Gleason KT, Gray MC, Rushtonn AJ, Nteliopoulos G, Hastings RK, Goddard K, Ions LM, Palmieri C, Ali S, Stebbing J, Coombes RC.
Circulating tumour DNA profiling from Breast Cancer screening through to metastatic disease.
JCO Precision Oncology, 2021;24:5.
Zhu L, Wang Z, Sun Y, Giamas G, Stebbing J, Yu Z, Peng L.
A prediction model using alternative splicing events and the immune microenvironment signature in lung adenocarcinoma.
Frontiers in Oncology, 2021;11:778637.
Malczewska A, Frampton AE, Mato Prado M, Ameri S, Dabrowska AF, Zagorac S, Clift AK, Kos-Kudła B, Faiz O, Stebbing J, Castellano L, Frilling A
Circulating MicroRNAs in Small-bowel Neuroendocrine Tumors: A Potential Tool for Diagnosis and Assessment of Effectiveness of Surgical Resection.
Annals of Surgery, 2021;274:e1-e9.
Peng L, Li J, Wu J, Xu B, Wang Z, Giamas G, Stebbing J, Yu Z.
A pan-cancer analysis of SMARCA4 alterations in human cancers.
Frontiers in Oncology, 2021;12:762598.
Peng L, Lu D, Xia Y, Hong S, Selvaggi G, Stebbing J, Sun Y, Liang F.
Efficacy and safety of first line treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a Bayesian network meta-analysis.
Frontiers in Oncology, 2021;11:754-768.